The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | An update on the Phase I trial of BMS-986393, a novel GPRC5D-targeted CAR-T, in R/R myeloma
Susan Bal, MD, University of Alabama at Birmingham, Birmingham, AL, discusses BMS-986393, an autologous CAR-T product that targets GPRC5D, in the treatment of relapsed/refractory (R/R) multiple myeloma. This novel agent has shown promising response rates in a Phase I trial, which found a recommended dose to be taken into Phase II trials. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
